There are no proven peptides for TBI and concussion. No peptide is approved to treat traumatic brain injury. The best-studied one, Cerebrolysin, showed a small-to-medium benefit in two small manufacturer-sponsored trials of moderate to severe TBI (185 patients combined),[5][6] but it has not been tested in concussion and is not FDA-approved. A large trial of the hormone erythropoietin (EPO) found no benefit,[7] and nerinetide was studied in stroke, where it also failed.[8][9] Peptides like BPC-157 and TB-500 have only animal data.
This guide grades the evidence. For related topics, see our nootropic peptides hub.
Evidence at a glance
| Peptide or treatment | Evidence level | What was shown | FDA status | Our profile |
|---|---|---|---|---|
| Emergency and neurocritical care; graded return to activity | Standard of care | Guideline-based diagnosis and management[2] | n/a | n/a |
| Cerebrolysin | Small human studies | Small-to-medium benefit on combined scales at 90 days[5] | Not approved | Cerebrolysin |
| Erythropoietin (EPO) | Human RCTs | No improvement in 606 patients[7] | Approved for anemia, not TBI | EPO |
| Nerinetide | Human RCTs (stroke only) | No benefit in two large stroke trials[8][9] | Not approved | n/a |
| Thymosin beta-4 / TB-500 | Animal or lab only | Better recovery in rats[10] | Not approved | TB-500 |
| BPC-157, Dihexa | Animal or lab only | No human brain-injury trials | Not approved | BPC-157, Dihexa |
Start with emergency and proven care
Moderate and severe brain injuries are treated in hospitals with imaging, close monitoring of brain pressure and oxygen, sometimes surgery, and then rehabilitation. For mild TBI and concussion, the CDC’s pediatric guideline sets out recommendations for imaging, symptom scales, cognitive testing and management.[2] In practice, this means a short period of relative rest, a gradual return to school, work and sport, and treatment of symptoms such as headache and poor sleep. Most people with a concussion recover, but symptoms that persist deserve follow-up.
Cerebrolysin: the CAPTAIN trials
Cerebrolysin is an injected mix of small peptides and amino acids from pig brain. Its maker says it is not registered with FDA or approved for sale in the US.[11]
- CAPTAIN I: this Asian-Pacific trial was stopped early because of poor recruitment.[6] In the 46 people enrolled, Cerebrolysin narrowly missed significance on its main combined outcome in the full analysis, though it reached significance among those who completed treatment as planned.[3]
- CAPTAIN II: a single-center trial of 142 patients with moderate to severe TBI. Patients got 50 mL a day for 10 days, then two more 10-day cycles at a lower dose. On a combined set of 13 outcome scales at 90 days, the effect was “small-to-medium” and statistically significant.[4]
- Combined analysis: pooling 185 patients from both trials, the authors again found a small-to-medium benefit at days 30 and 90, with side effects similar to placebo.[5]
These results are encouraging but limited: the trials were small, sponsored by the manufacturer,[6] and used a combined “ensemble” of outcomes rather than a single standard measure such as the Glasgow Outcome Scale. In stroke trials, a Cochrane review found a possible rise in non-fatal serious adverse events with Cerebrolysin.[12] No trial has tested it in concussion.
EPO: a large, negative trial
Erythropoietin is a hormone that boosts red blood cell production and showed brain-protective effects in animals. In the EPO-TBI trial, 606 patients with moderate or severe TBI got weekly EPO or placebo for up to three doses. At 6 months, the share with severe disability or death was 44% with EPO and 45% with placebo, no meaningful difference.[7] See our EPO profile.
Nerinetide: important context
Nerinetide is a 20-amino-acid peptide designed to protect brain cells from damage when blood flow is cut off. It is often mentioned in brain-injury discussions, but its trials were in ischemic stroke, not TBI:
- ESCAPE-NA1 (2020): in 1,105 stroke patients having clot removal, 61.4% on nerinetide and 59.2% on placebo had a good outcome at 90 days, not a significant difference.[8]
- ESCAPE-NEXT (2025): in 850 patients who did not get clot-busting drugs, good outcomes were 45% versus 46%.[9]
Nerinetide has no published TBI trials. Read more in peptides for stroke recovery.
TB-500, BPC-157 and Dihexa: animal data only
- Thymosin beta-4, the natural protein that TB-500 is based on, improved movement and memory and reduced brain damage in rats when given 6 hours after injury.[10] There are no human TBI trials.
- BPC-157 and Dihexa are promoted online for brain healing, but neither has human brain-injury trials. FDA has listed several research peptides among compounding substances with safety concerns.[13]
See BPC-157 vs TB-500 for more on those two.
Why brain-injury drugs keep failing
Drugs that protected the brain in animals, including EPO, have often failed in human TBI trials.[7] Brain injuries vary widely in type, location and severity, while animal models usually test one controlled injury with treatment at a precise time. In people, treatment often starts later and patients differ in age and health. That is why a promising rat result, such as thymosin beta-4’s,[10] is only a first step, and why products sold online with brain-healing claims deserve caution.
Questions to ask your care team
- Which rehabilitation services, such as physical, occupational, speech or cognitive therapy, fit my recovery?
- Which symptoms should prompt a return visit?
- Are there clinical trials I could join?
- When is it safe to return to driving, work, school or sport?
For related reading, see best peptides for cognition, peptides for depression and Dihexa vs Semax vs Selank.
